UCB

Highly Engaged Employees

UCB, a global biopharmaceutical leader, was founded in 1928 and is headquartered in Brussels, Belgium. The company is dedicated to discovering, developing, and commercializing innovative medicines for individuals facing severe neurological and autoimmune conditions. UCB's strategic focus encompasses neurology, addressing conditions such as epilepsy and Parkinson's disease, and immunology, targeting diseases like rheumatoid arthritis, Crohn's disease, psoriasis, and axial spondyloarthritis. For detailed geographic information, Learn about UCB's global headquarters. The company maintains a significant presence in the United States, with its U.S. headquarters situated in Smyrna, Georgia, alongside other U.S. sites supporting critical functions like clinical development and research.

The company's robust product portfolio includes key treatments such as Cimzia, Vimpat, Keppra, Briviact, Neupro, Bimzelx, Evenity, and Fintepla. UCB distinguishes itself by deeply integrating patient and caregiver insights directly into its research and development processes, ensuring its innovations are aligned with real-world needs. This patient-centric approach is fundamental to its operations, fostering a culture of scientific excellence and empathy. To understand the people driving these advancements, Meet UCB's team for insights into their leadership and expertise.

Operating in over 40 countries worldwide, UCB generates substantial revenue, reported at $5.9B, and employs a workforce of Over 10,000 employees. This extensive global reach allows UCB to address diverse patient populations and healthcare systems effectively. The company is committed to advancing health equity and creating sustainable value through its scientific endeavors and business practices, aiming to improve the lives of patients globally.